NICE have suggested that the ORBIT bleeding risk score should be used (in comparison to other bleeding risk scoring systems such as HAS-BLED) in assessing the risk of bleeding when a patient commences, or is under review, regarding anticoagulation therapy in atrial fibrillation (1).
NICE state that "because evidence shows that it has a higher accuracy in predicting absolute bleeding risk than other bleeding risk tools. Accurate knowledge of bleeding risk supports shared decision making and has practical benefits, for example, increasing patient confidence and willingness to accept treatment when risk is low and prompting discussion of risk reduction when risk is high. Although ORBIT is the best tool for this purpose, other bleeding risk tools may need to be used until it is embedded in clinical pathways and electronic systems"
O'Brien et al devised the ORBIT bleeding risk scoring system:
Risk Factor For Bleeding | Points Attributed |
(older (75 years or older) | 1 point |
reduced haemoglobin (<13 mg/dL in men and <12 mg/dL in women), haematocrit (<40% in men and <36% in women) or history of anaemia | 2 points |
bleeding history | 2 points |
insufficient kidney function (eGFR < 60 mg/dL/1.73 m2) | 1 point |
treatment with an antiplatelet agent | 1 point |
ORBIT Score | Risk group | Bleeds per 100 patient-years |
0-2 | Low | 2.4 |
3 | Medium | 4.7 |
4-7 | High | 8.1 |
Click here for online ORBIT risk calculator
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.